https://pharmadevicenews.com/pimjetmi-shrank-tumours-in-56-of-tgct-patients-can-merck-kgaa-break-through-an-increasingly-crowded-rare-tumour-market/ PharmaDeviceNews en 2026-11-12T07:09:51+00:00 Pimjetmi shrank tumours in 56% of TGCT patients. Can Merck KGaA break through an increasingly crowded rare-tumour market? Abbisko Medicine, EMD Serono, MANEUVER, Merck KGaA, pimicotinib, Pimjetmi, Romvimza, Turalio https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/risto-cel-stopped-severe-sickle-cell-crises-long-enough-for-beam-to-plan-a-bla-why-did-the-stock-still-fall/ PharmaDeviceNews en 2026-11-12T04:07:51+00:00 Risto-cel stopped severe sickle cell crises long enough for Beam to plan a BLA. Why did the stock still fall? BEACON, Beam Therapeutics, Casgevy, Genetix Biotherapeutics, LYFGENIA, risto-cel, ristoglogene autogetemcel, United States Food and Drug Administration, Vertex Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2026/07/Vertex-wins-broader-CASGEVY-approval-as-pediatric-gene-therapy-enters-a-new-phase-e1782965191835.webp https://pharmadevicenews.com/abbott-just-put-physiologic-pacing-and-defibrillation-on-one-lead-can-ultisynq-change-how-icds-are-implanted/ PharmaDeviceNews en 2026-11-12T04:01:59+00:00 Abbott just put physiologic pacing and defibrillation on one lead. Can UltiSynq change how ICDs are implanted? Abbott Laboratories, ASCEND CSP, UltiSynq, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/two-phase-3-wins-put-comp360-before-the-fda-can-compass-pathways-turn-psilocybin-into-a-mainstream-depression-treatment/ PharmaDeviceNews en 2026-11-12T03:58:18+00:00 Two Phase 3 wins put COMP360 before the FDA. Can Compass Pathways turn psilocybin into a mainstream depression treatment? COMP005, COMP006, COMP360, COMPASS Pathways https://pharmadevicenews.com/wp-content/uploads/2026/05/Evecxia-Therapeutics-positions-EVX-101-as-adjunctive-therapy-for-OCD-and-depression-e1780030000546.webp https://pharmadevicenews.com/genedx-analysed-more-than-300000-patients-and-found-actionable-results-in-62-of-positive-cases-why-did-wgs-crash-17/ PharmaDeviceNews en 2026-11-12T03:53:20+00:00 GeneDx analysed more than 300,000 patients and found actionable results in 62% of positive cases. Why did WGS crash 17%? ExomeDx, GeneDx, GeneDx Infinity, GenomeDx, National Society of Genetic Counselors https://pharmadevicenews.com/wp-content/uploads/2026/05/Inocras-CancerVision-data-point-to-a-harder-question-for-ovarian-cancer-diagnostics-e1779511076970.webp https://pharmadevicenews.com/asundexian-failed-in-atrial-fibrillation-then-became-the-first-factor-xia-drug-approved-what-did-bayer-get-right/ PharmaDeviceNews en 2026-11-11T07:24:17+00:00 Asundexian failed in atrial fibrillation, then became the first Factor XIa drug approved. What did Bayer get right? asundexian, Bayer AG, LIBREXIA-STROKE, milvexian, OCEANIC-AF, OCEANIC-STROKE, Sunharbo, United States Food and Drug Administration, Xarelto https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/can-sunharbo-become-bayers-next-cardiovascular-blockbuster-after-xarelto/ PharmaDeviceNews en 2026-11-11T07:21:36+00:00 Can Sunharbo become Bayer’s next cardiovascular blockbuster after Xarelto? asundexian, Bayer, OCEANIC-AF, OCEANIC-STROKE, Sunharbo, U.S. Food and Drug Administration, Xarelto https://pharmadevicenews.com/wp-content/uploads/2026/06/Penumbra-THUNDERBOLT-FDA-clearance-raises-the-stakes-in-stroke-thrombectomy-technology-e1781242935321.webp https://pharmadevicenews.com/biogen-and-ucbs-lupus-drug-reached-sustained-remission-in-more-patients-why-the-real-test-is-still-two-years-away/ PharmaDeviceNews en 2026-11-11T07:18:22+00:00 Biogen and UCB’s lupus drug reached sustained remission in more patients. Why the real test is still two years away American College of Rheumatology, AstraZeneca, Benlysta, Biogen Inc., dapirolizumab pegol, GSK, PHOENYCS FLY, PHOENYCS GO, Saphnelo, UCB SA https://pharmadevicenews.com/wp-content/uploads/2026/10/Autoimmune-disease-research-e1793144740150.webp https://pharmadevicenews.com/caplyta-improved-bipolar-mania-by-day-3-in-two-phase-3-trials-can-johnson-johnson-unlock-another-blockbuster-indication/ PharmaDeviceNews en 2026-11-11T07:15:09+00:00 CAPLYTA improved bipolar mania by Day 3 in two Phase 3 trials. Can Johnson & Johnson unlock another blockbuster indication? CAPLYTA, Intra-Cellular Therapies, Johnson & Johnson, lumateperone, Study 451, Study 452, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp https://pharmadevicenews.com/argenx-just-committed-up-to-1-15bn-to-a-biotech-with-no-disclosed-clinical-drug-what-is-it-really-buying/ PharmaDeviceNews en 2026-11-11T04:13:46+00:00 argenx just committed up to $1.15bn to a biotech with no disclosed clinical drug. What is it really buying? argenx, Cameron Pye, FB102, Forte Biosciences, Karen Massey, Unnatural Products, Vyvgart https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/optune-mya-doubled-median-time-to-brain-progression-why-did-the-fda-still-refuse-to-approve-it/ PharmaDeviceNews en 2026-11-11T03:51:10+00:00 Optune Mya doubled median time to brain progression. Why did the FDA still refuse to approve it? METIS, NovoCure Limited, Optune Gio, Optune Lua, Optune Mya, Tumor Treating Fields, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-13-2026-08_31_27-PM-e1789311742102.webp https://pharmadevicenews.com/roche-wants-to-treat-alzheimers-before-memory-loss-begins-can-a-blood-test-and-brainshuttle-antibody-make-prevention-possible/ PharmaDeviceNews en 2026-11-11T03:47:17+00:00 Roche wants to treat Alzheimer’s before memory loss begins. Can a blood test and Brainshuttle antibody make prevention possible? Clinical Trials on Alzheimer’s Disease, Elecsys pTau217, F. Hoffmann-La Roche Ltd, Genentech, PrevenTRON, RG6434, Roche Diagnostics, TARBELA-AD, TRONTIER, trontinemab, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic-image.webp https://pharmadevicenews.com/foundayo-cut-sleep-apnea-events-by-44-without-pap-can-lilly-turn-an-obesity-pill-into-its-next-osa-franchise/ PharmaDeviceNews en 2026-11-11T03:42:59+00:00 Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise? ATTAIN-OSA, Chugai Pharmaceutical Co. Ltd., Eli Lilly and Company, Foundayo, orforglipron, tirzepatide, U.S. Food and Drug Administration, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp